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Purpose: To investigate the development of corneal neovascularization, the corneal expression of vascular endothelial
growth factor (VEGF), and the antiangiogenic effects of a VEGF-inhibitory antibody during experimental keratomycosis.
Methods: Scarified corneas of BALB/c mice were topically inoculated with Candida albicans and monitored daily for
corneal neovascularization. A murine gene microarray compared infected corneas to controls 1 day after inoculation. Real-
time reverse transcriptase polymerase chain reaction (RT-PCR) determined levels of genes encoding VEGF-A, VEGF-
B, VEGF-C, and VEGF-D and placental growth factor in infected, mock-inoculated, and normal corneas. Immunostaining
localized VEGF-A in corneal sections. An anti-VEGF-A antibody that binds to murine VEGF was evaluated for effects
on corneal neovascularization and fungal recovery.
Results: Eyes with C. albicans keratitis manifested limbal capillary budding on the second postinoculation day, and
intrastromal neovascular tufts subsequently grew at a mean rate of 250±80 μm/day. One day after the onset of C. albicans
keratitis, VEGF-A was upregulated 12.5 fold (p=0.01) by microarray and 8.8 fold (p=0.004) by real-time RT-PCR,
followed by a measured decline toward baseline over one week. VEGF-A was present in the epithelium and stroma of
infected corneas. Scarification alone did not alter VEGF expression compared to the normal cornea. Anti-VEGF-A
antibody significantly (p<0.01) decreased the formation of new corneal blood vessels during experimental keratomycosis
without adversely affecting the fungal load of C. albicans keratitis.
Conclusions: Untreated C. albicans keratitis induces VEGF-A and leads to progressive corneal neovascularization that
is preventable by a VEGF-blocking antibody.
New vessels form and grow in the normally avascular
cornea when the homeostatic balance is upset by infection and
inflammation [1,2]. Angiogenic factors that promote ocular
neovascularization include the vascular endothelial growth
factor (VEGF) family [3]. As neovascularization may worsen
visual prognosis, anti-VEGF inhibitors offer the possibility of
controlling sight-threatening neovascular disorders of the eye
[4,5].
Corneal  neovascularization  complicates  Candida
albicans  keratitis  [6],  but  the  molecular  pathogenesis  of
angiogenesis during fungal keratitis has not yet been studied.
We used a murine model of posttraumatic C. albicans keratitis
to determine the corneal VEGF profile during the onset and
progression of fungal keratitis. We also studied the effect of
VEGF-blocking treatment during experimental C. albicans
keratitis. Because a humanized anti-VEGF antibody such as
bevacizumab weakly interacts with murine VEGF-A [7], we
used a cross-reactive monoclonal antibody constructed with a
murine  immunoglobulin  constant  domain  to  block  the
interaction of murine VEGF with ocular VEGF receptors [8].
Before studying the efficacy of subconjunctival or topical
application in the mouse model, we used a proof-of-principle
approach by administering anti-VEGF antibody systemically
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at a dosage capable of inhibiting corneal neovasularization
[9].
METHODS
Fungi: C. albicans strain SC5314 is a clinical isolate capable
of producing experimental keratomycosis [10]. Yeasts were
cultured on Sabouraud dextrose agar (Difco, Detroit, MI) for
3 days at 25 °C. Colonies were harvested and diluted in sterile
phosphate-buffered  saline  (PBS)  to  yield  2×105  colony-
forming units (CFU)/μl based on an optical density (OD) at
600 (OD600) nm with a conversion factor of 1 OD600 unit equal
to 3×107 CFU/ml.
Animals: Animals were treated in accordance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research under protocols approved by the Baylor College of
Medicine  Institutional  Animal  Care  and  Use  Committee.
Female BALB/c mice and C57BL/6J mice 6 to 8 weeks of age
(Harlan Sprague-Dawley, Houston, TX) were anesthetized
intraperitoneally with ketamine, xylazine, and acepromazine,
and  the  corneas  of  right  eyes  were  superficially  scarified
[10]. A 5 μl inoculum of either C. albicans (1×106 CFU) or
sterilized PBS buffer was topically applied to eyes of infected
and control groups, respectively. Mice were monitored daily
for 7 days post inoculation (p.i.) using a dissecting microscope
to  categorize  corneal  inflammation  [10].  The  amount  of
corneal neovascularization was assessed by a scoring system
modified from a semiquantitative method [11] that assigned
grades of 0 to 4 for number, density, and length of visible
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1988corneal blood vessels (Table 1). Corneal photographs with the
eye positioned in lateral profile were captured with a Zeiss
photo slit-lamp and Nikon digital camera. Imported images
were  converted  to  linear  gray-scale  equivalents  using
SigmaScan image-analysis software (Systat, Richmond, CA),
and the limbal arcade and neovascular network were manually
delineated based on adjacent pixel values for edge detection
[12].
RNA extraction: Mice were sacrificed 1, 3, and 7 days p.i.,
and  eyes  were  enucleated  for  analysis.  Corneas  were
dissected,  and  surrounding  conjunctiva  and  uvea  were
removed. Three cornea pools (5 corneas/pool) were prepared
from C. albicans-infected and mock control groups at days 1,
3,  and  7  p.i.  and  from  untreated  normal  mouse  corneas,
respectively. RNA was extracted by a previously reported
procedure  [13].  Total  RNA  was  isolated  with  RNeasy
MicroKit columns (Qiagen, Valencia, CA). Samples were
treated with DNase (Qiagen) to exclude DNA contamination
and stored at -80 °C until use.
Gene  microarray:  Microarray  was  performed  by  the
Microarray Core Facility of Baylor College of Medicine as
Figure 1. Severity evaluation of corneal neovascularization during
C. albicans infection. Relative corneal neovascularization (NV) was
compared  in  eyes  with  C.  albicans  keratitis  (infected)  and  in
scarified, mock-inoculated eyes (control). Each point represents the
mean neovascularization score (±SD) of 5 eyes at each day following
topical inoculation.
reported  [13].  After  checking  RNA  samples  for  quality
assurance,  Genechip  (Affymetrix,  Santa  Clara,  CA)
microarray protocols were applied to qualified samples of 3
five-cornea pools from C. albicans-infected and mock control
groups for two cycles of amplification. Images and quality
control  metrics  were  recorded  using  Affymetrix  GCOS
software  version  1.4,  and  raw  signal  intensity  data  were
adjusted  and  analyzed  with  BioConductor  software.  The
criterion for significance of differentially regulated genes was
>2 fold change with adjusted p<0.05.
Quantitative polymerase chain reaction: Total RNA isolated
from 3 pools (5 corneas/pool) at 1, 3, or 7 days p.i. respectively
was quantified by absorbance at OD260. The first-strand cDNA
was synthesized from 0.4 μg of total RNA with Ready-To-Go
You-Prime  First-Strand  Beads  (GE  Healthcare,  Princeton,
NJ) and random hexamers (Applied Biosystems, Foster City,
CA). Real-time PCR was performed using TaqMan Gene
Expression Master Mix and Assays (Applied Biosystems).
Primers specific for VEGF-A, VEGF-B, VEGF-C, VEGF-D,
and  placental  growth  factor  (PlGF)  transcripts  (Applied
Biosystems) were used to quantify gene expression levels.
The  threshold  cycle  (CT)  for  each  target  mRNA  was
normalized  to  glyceraldehyde-3-phosphate  dehydrogenase
(GAPDH) mRNA and averaged. Three five-cornea pools were
processed for each group. Two-group comparisons were done
using the Student t-test, and three-group comparisons used
one-way analysis of variance (ANOVA). For longitudinal
analysis of VEGF transcriptional levels, mean results were
compared  with  ANOVA  using  a  pairwise  multiple
comparison procedure. A p<0.05 was considered statistically
significant.
Immunofluorescence: Three eyes from each group obtained 1
day p.i. were embedded in OCT compound (Sakura Finetek,
Torrance, CA), snap-frozen in liquid nitrogen, and sectioned
at 15 μm thickness. Sections were thawed, dehydrated, and
fixed in 2% paraformaldehyde then blocked with 10% normal
donkey  serum  (Jackson  ImmunoResearch  Laboratories,
Philadelphia,  PA).  Immunofluorescent  staining  was
performed as reported [14]. Polyclonal goat antibody to the
NH2-terminus  of  mouse  VEGF-A  (sc-1836;  Santa  Cruz
Biotechnology,  Santa  Cruz,  CA)  was  diluted  1:100,  and
applied to the blocked sections that were incubated overnight
at 4 °C. Secondary Alexa-Fluor 488-conjugated donkey anti-
goat  antibody  (Invitrogen,  Carlsbad,  CA)  was  applied  to
TABLE 1. CRITERIA USED IN GRADING SEVERITY OF CORNEAL NEOVASCULARIZATION.
  Number of quadrants with corneal
Score                      neovascularization
Number of corneal vessels/
quadrant
Proportionate length of longest corneal vessels
between limbus and corneal center
1 1 1-5 0.05-0.25
2 2 6-10 0.26-0.50
3 3 11-15 0.51-0.75
4 4 >15 >0.75
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1989Figure 2. Corneal neovascularization during 7 days of follow up during murine C. albicans infection. Daily progression over one week of
corneal neovascularization in mouse eyes with C. albicans keratitis (panels A to G from day 1 p.i. to day 7 p.i., respectively). No abnormal
corneal blood vessels occurred in the mock-inoculated control (H).
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1990sections that were incubated in a dark chamber for 1 h and
counterstained with propidium iodine (Invitrogen) in Gel/
Mount (Biomeda, Foster City, CA). Sections were observed
with a laser-scanning confocal microscope (LSM 510; Zeiss,
Thornwood,  NY)  with  488-  and  543-nm  excitation  and
emission  filters.  Images  were  acquired  with  a  40×  oil-
immersion  objective  and  processed  using  Zeiss  LSM-PC
software.
Anti-VEGF treatment: A buffered formulation of a phage
library-derived  anti-VEGF  antibody,  B20-4.1.1  [8],  that
blocks  both   human  and   mouse  VEGF-A  (Genentech, 
South   San   Francisco,   CA)   was   diluted   in  PBS  to   a
dosage   of   5   mg/kg.   Five   mice   were   allocated   to
treated  and  control  groups,  respectively,  and  each  animal
received  200  µl  of  either   B20-4.1.1  or  PBS,  injected
intraperitoneally 5 days, 3 days, and 1 day before corneal
scarification  and  topical  inoculation  of  C.  albicans  1×106
CFU/5  μl.  Eyes  were  observed  daily  with  a  dissecting
microscope to grade the severity of keratitis and the extent of
corneal neovascularization.
Quantitative fungal culture: Each of ten additional BALB/c
mice or C57BL/6J mice were treated intraperitoneally with
either B20-4.1.1 or PBS on 5 days, 3 days, and 1 day before
fungal  inoculation  and  then  sacrificed  one  day  p.i.  for
quantitative  fungal  recovery  from  excised  corneas  by
previously reported method with some modifications [10].
Excised corneas were homogenized by a frosted-glass grinder
with 500 μl PBS, and the homogenate aliquot was 10 fold
diluted and cultured on Sabouraud dextrose agar for 4 days at
25  °C.  Visible  colonies  were  counted  and  compared  in
B20-4.1.1- and PBS-treated groups.
RESULTS
Experimental fungal keratitis: All corneas inoculated with C.
albicans  developed  signs  of  inflammation  and
neovascularization.  Congestion  of  the  limbal  pericorneal
plexus  began  1  day  p.i.,  and  capillary  budding  of  limbal
vessels occurred 1 to 2 days later (Figure 1). Corneal vessels
continued to  extend toward the  area of  inflammation at the
rate  of  0.25±0.08 mm/day  and reached  the central  cornea
on  days  6 to 7 (Figure 2).   Neither corneal inflammation nor
neovascularization occurred among mock controls or normal
mice.
VEGF gene expression profile: Gene arrays of C. albicans-
infected corneas and mock-inoculated control corneas were
compared  for  VEGF  expression  (Table  2).  Ratios  of
expression  levels  at  1  day  p.i.  showed  that  VEGF-A  was
upregulated an average of 12.5 fold (p=0.01). VEGF-B was
downregulated -2.8 fold (p=0.002). Neither VEGF-C, VEGF-
D, nor PlGF differed significantly between infected eyes and
controls. Transcript levels detected by quantitative real-time
RT-PCR were consistent with microarray findings (Table 2).
Table  3  shows  the  average  real-time  RT-PCR  CT  values
among  the  three  groups.  Compared  to  mock-inoculated
controls, VEGF-A transcript level was upregulated 8.1 fold
(p=0.004) at day 1 p.i., followed by 5.4 fold (p=0.01) at day
3 p.i. and 2.5 fold (p=0.23) at day 7 p.i. Other VEGF family
members  did  not  increase  significantly  during  follow  up.
VEGF-B   was   downregulated    -2.5   fold    (p=0.04),   and 
VEGF-D  was  downregulated -3.9 fold (p=0.0004) on day 1 
p.i. Compared to normal eyes, mock-inoculated controls were
not significantly different in VEGF-A,  VEGF-B,  VEGF-C,
VEGF-D, or PlGF expression levels.
VEGF-A  protein  expression  pattern:  The  in  situ  pattern
determined by immunofluorescent staining showed moderate
epithelial  staining  for  VEGF-A  among  normal  eyes  and
scarified corneas. At 1 day p.i., corneas from infected eyes
had increased staining for VEGF-A throughout epithelial and
stromal layers (Figure 3).
TABLE 2. MICROARRAY ANALYSIS AND REAL-TIME RT-PCR CONFIRMATION OF VEGF EXPRESSION RATIOS COMPARING C. ALBICANS KERATITIS TO MOCK-INFECTED
CONTROLS.
  GenBank
accession
number
Mean signal intensity
ratio±SD by microarray
                  Pooled mean signal
intensity ratio±SD by
microarray
Mean fold change±SD
by real-time RT-PCR p#
VEGF-A AC127690 11.5±2.9 0.002 12.5±4.4 0.65 8.79±4.46 0.27
  AB086118 13.4±6.1 0.01
VEGF-B AK148188 -2.8±0.2 0.002 -2.8±0.2 1.0 -2.87±1.69 0.95
VEGF-C AC120547 1.4±0.2 0.53 1.3±0.2 0.36 -0.90±2.19 0.008
  AC120547 1.3±0.1 0.33
  AC163012 1.2±0.1 0.22
VEGF-D BC030037 -1.4±0.3 0.09 -1.9±1.6 0.48 -3.91±0.67 0.066
  BC062809 -1.5±2.3 0.23
  BC080770 -2.9±1.5 0.022
PlGF AK042891 1.8±0.6 0.13 1.8±0.6 1.0 0.50±1.68 0.28
The asterisk indicates statistical comparison of microarray signals between infected and control groups. The double asterisk
indicates statistical comparison of gene expression results among genomic probes. The sharp (hash mark) indicates statistical
comparison of pooled microarray and real-time RT-PCR results. Abbreviations in the table are: PlGF, placental growth factor;
RT-PCR, reverse transcription-polymerase chain reaction; SD, standard deviation; VEGF, vascular endothelial growth factor.
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p** p* MoleculeVEGF kinetic analysis: Real-time RT-PCR on total RNA
extracted  from  groups  of  five-cornea  pools  showed
differences  between  C.  albicans  keratitis  and  scarified
controls at 1, 3, and 7 days p.i. (Table 3). In infected corneas,
VEGF-A  transcripts  were  upregulated  on  day  1  p.i.  then
declined toward baseline levels but remained significantly
increased at 3 days p.i. (Figure 4). VEGF-B and VEGF-D were
slightly downregulated at day 1 p.i., and VEGF-B remained
relatively downregulated in infected corneas on day 3 p.i. By
day  7  p.i.,  VEGF-B  and  VEGF-D  levels  in  experimental
corneas were similar to controls and normal eyes. VEGF-C
and PlGF remained unchanged in infected corneas compared
to controls.
Treatment effects of anti-VEGF antibody: Compared with
PBS-injected  animals,  corneal  neovascularization  in  anti-
VEGF-treated mice was significantly reduced, and this effect
persisted until 15 days p.i. when observations ceased. An
inhibitory effect was apparent by 3 days p.i. (p=0.008), and
treated  animals  continued  to  have  less  corneal
neovascularization on each subsequent day (p<0.001) (Figure
5). At 7 days p.i., the average vascularization score of 6.2±0.5
in treated mice remained significantly lower (p=0.0002) than
the  average  score  of  9.6±0.6  in  controls.  Image  analysis
confirmed  that  fewer  blood  vessels  were  present  in  the
peripheral cornea in anti-VEGF-treated mice compared to
PBS-treated  mice  (Figure  6).  Severity  scores  of  corneal
Figure 3. Molecular expression patterns
in  situ  in  corneas  with  C.  albicans
infection.  VEGF-A  expression  was
compared  between  corneas  with  C.
albicans keratitis (Infected) and mock-
inoculated  controls  (Mock).  Negative
controls  lacked  primary  antibody
(Control”.  Corneal  sections  were
processed  with  anti-VEGF-A
monoclonal  antibodies  (VEGF-A).
Immunofluorescence showed VEGF-A
in  the  healed  epithelium  of  scarified
corneas and within the epithelium and
stroma  one  day  after  the  onset  of
experimental  C.  albicans  keratitis.
Original magnification, 10×. Scale bar,
20 μm.
TABLE 3. QUANTITATIVE GENE EXPRESSION LEVELS.
                                                         Normal
                             Gene cornea
Mock-infected cornea Infected cornea
Day 1 Day 3 Day 7 Day 1 Day 3 Day 7
VEGF-A 7.20±0.52 7.73±0.36 7.99±0.30 6.84±0.97 4.71±0.80 5.56±0.91 5.54±1.26
VEGF-B 5.72±0.38 6.64±0.17 6.59±0.51 5.83±0.95 7.98±0.78 8.05±0.77 6.38±1.24
VEGF-C 9.80±0.07 9.92±0.21 10.97±0.65 9.49±2.10 10.34±0.92 10.69±0.28 8.70±1.61
VEGF-D 8.49±0.58 7.60±0.12 7.85±0.19 7.90±0.07 9.55±0.28 8.54±0.50 7.36±0.19
PlGF 8.50±0.98 8.70±0.14 8.14±0.33 8.18±0.57 8.52±0.76 8.60±0.51 7.64±0.60
Mean threshold cycle number ±standard deviation normalized to GAPDH by real-time RT-PCR.
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1992inflammation  were  not  significantly  different  between
treatment and control groups at any day during one week of
observation (p>0.05), although slightly more prominent iris
vessels were noted in the anti-VEGF-treated group. Cultures
from excised BALB/c mice corneas at 1 day p.i. showed no
significant difference (p=0.63) in the mean±SD number of
viable  fungi  recovered  from  PBS-treated  mice
(28,750±37,979 CFU/cornea) compared to those treated with
anti-VEGF antibody (20,110±9,550 CFU/cornea). Similarly,
for C57BL/6J mice, no significant difference (p=0.62) was
found for the recovery cultures between PBS-treated mice
(20,100±3,719 CFU/cornea) and anti-VEGF antibody-treated
mice (21,750±6,072 CFU/cornea).
DISCUSSION
Fungal infection of the cornea provokes stromal inflammation
and  neovascularization  [6].  The  innate  immune  response
triggers the production of inflammatory mediators soon after
fungal  adherence  and  invasion  [13,14].  Corneal
neovascularization  occurs  in  response  to  angiogenic
mediators released by leukocytes and corneal cells [15,16].
We confirmed that C. albicans keratitis incites corneal
neovascularization, with angiogenesis beginning sooner in the
infected mouse eye than in the rabbit model [6]. New blood
vessels bud from the murine pericorneal plexus within 2 to 3
days after the onset of corneal infection and inflammation.
Progressive neovascular extension toward the central cornea
contributes to corneal opacification during fungal keratitis.
VEGF-A  has  a  pivotal  role  in  inflammatory
neovascularization  [17].  During  experimental  keratitis
Figure  4.  Relative  VEGF  gene  expression  during  C.  albicans
keratitis. Differential gene expression ratios of vascular endothelial
growth factors were determined by real-time RT-PCR throughout the
first week. Gene expression levels in corneas with posttraumatic C.
albicans  keratitis  were  compared  to  levels  in  scarified,  mock-
inoculated control corneas. Horizontal dashed lines indicate 2 fold
threshold expression levels.
VEGF-A is increased throughout the corneal epithelium and
stroma [18,19] and is extensively expressed in the inflamed,
vascularized cornea [20,21]. Our results with comparative
genomics and immunopathology confirmed that VEGF-A is
present  in  the  corneal  epithelium  [22]  and  increases
throughout the cornea soon after the onset of experimental
fungal keratitis. VEGF-A expression is closely followed by
limbal vascular sprouting into the peripheral conea.
The  brisk  increase  of  VEGF-A  during  C.  albicans
keratitis  parallels  VEGF  production  during  experimental
Pseudomonas aeruginosa keratitis [23-25]. Our findings are
also consistent with studies showing that systemic infection
by C. albicans produces neovascularization adjacent to fungal
microabscesses  [26].  VEGF  expression  increases  upon
exposure  to  virulent  C.  albicans  [27]  and  triggers  local
cytokine production. The upsurge in interleukins and other
local cytokines that occurs at the onset of C. albicans keratitis
[13]  leads  to  recruitment  of  leukocytes  that  contribute  to
VEGF production [23,28].
Our  findings  indicate  that  VEGF  mediates  corneal
neovascularization  during  keratomycosis.  VEGF-deficient
transgenic mice could not be used to confirm this inference
because VEGF is essential for embryogenesis and survival
[29,30].  VEGF-A  appears  closely  involved  with  the
neovascular  process  during  fungal  keratitis.  Our  previous
studies  also  suggest  that  proinflammatory  matrix
metalloproteinases  (MMPs)  may  have  a  role  in  corneal
Figure  5.  Effect  of  anti-VEGF  pretreatment  on  corneal
neovascularization  during  fungal  keratitis.  Relative  severity  of
corneal neovascularization (NV) during 7 days of follow up in C.
albicans  keratitis  in  mice  treated  with  intraperitoneal  VEGF-
blocking  antibody  B20-4.1.1  (anti-VEGF)  compared  to  controls
receiving phosphate-buffered saline (PBS). Each point reprsents the
mean neovascularization score (±SD) of 5 eyes at each day following
topical  inoculation.  Asterisks  indicate  time  points  having  a
statistically significant (p<0.01) difference.
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1993neovascularization. MMP-9 increases during fungal keratitis
[14] and is capable of promoting angiogenesis during stromal
degradation [31]. Fungal keratitis consists of a coordinated
interplay  of  inflammatory  and  neovascular  mediators  that
offer possible targets for intervention.
Inhibitors of VEGF-A might have a therapeutic role in
the management of corneal disease. Corticosteroids and other
anti-inflammatory  drugs  reduce  vascular  ingrowth  during
fungal keratitis [6,32] but can potentiate fungal replication
[33]. Anti-VEGF antibodies provide a specific intervention to
slow the onset and progression of corneal neovascularization.
Bevacizumab  inhibits  inflammatory  corneal
neovascularization in experimental animal models [9,34-37].
Because this humanized antibody has weak activity against
murine VEGF [7], we used a monoclonal antibody that blocks
murine  VEGF-A  activity  and  examined  its  effects  on
experimental  fungal  keratitis  [8,38].  Systemic  anti-VEGF
administration effectively inhibited corneal angiogenesis that
occurs during C. albicans keratomycosis but did not adversely
alter corneal inflammation or fungal growth. The control of
corneal neovascularization by VEGF-blockade is a promising
adjunctive strategy in the management of microbial keratitis,
and further studies should  explore the safety and efficacy of
topical antiangiogenic agents in keratomycosis.
In summary, corneal neovascularization occurs soon after
the onset of corneal infection by C. albicans. Angiogenesis
complicating fungal keratitis likely results from production of
VEGF-A and other mediators such as MMP-9 that increase
during  corneal  infection  and  inflammation.  Inhibiting  the
activity of VEGF-A by a specific blocking antibody results in
reduced corneal neovascularization without any apparent or
unfavorable effects on innate immunity and fungal load. This
study identifies a specific target for adjunctive chemotherapy
aimed  at  reducing  the  sight-limiting  consequences  of
microbial keratitis.
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